Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
NCT ID: NCT01173874
Last Updated: 2017-04-11
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
120 participants
Study Classification
INTERVENTIONAL
Study Start Date
2010-07-31
Study Completion Date
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and Cognitive Assessment Interview).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Remediation Therapy for Participants With Late-Life Schizophrenia
NCT03695614
Schizophrenia
Cognitive Remediation
Late Life Schizophrenia
+2 more
COMPLETED
NA
Efficacy of Personalizing Cognitive Remediation for Schizophrenia by Targeting Impairments in Early Auditory Processing
NCT04554121
Schizophrenia
Schizoaffective Disorder
ACTIVE_NOT_RECRUITING
NA
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
NCT05182476
Schizophrenia
TERMINATED
PHASE2
Personalized and Scalable Cognitive Remediation Approaches
NCT01945333
Schizophrenia
Schizoaffective Disorder
COMPLETED
NA
Feasibility of Providing Cognitive Remediation to People With Schizophrenia in a Clinical Network
NCT00930150
Schizophrenia
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OVERVIEW \& SPECIFIC AIMS Marked cognitive impairment underlies much of the social \& occupational dysfunction associated with schizophrenia. Currently available antipsychotic medications are primarily effective in treating psychotic symptoms \& have demonstrated only limited potential in ameliorating cognitive deficits in schizophrenia patients.
Lurasidone is a novel compound synthesized by SEPRACOR, Inc.for the treatment of patients with schizophrenia \& bipolar disorder. It possesses high affinity for dopamine D2, serotonin 5-HT2A, 5-HT7, 5-HT1A \& noradrenaline α2C receptors. Compared with other atypical antipsychotics, lurasidone demonstrates similar binding affinities for the D2 \& 5-HT2A receptors, but greater affinity for serotonin 5-HT1A receptors. Lurasidone displays no affinity for histamine H1 or acetylcholine M1 receptors. In animal studies, lurasidone significantly reversed memory impairment induced by MK-801, an N-methyl-D-aspartate (NMDA) receptor antagonist, in a rat step-through type passive avoidance task. The maximum inhibitory effects of lurasidone were greater than those observed with risperidone, quetiapine, \& olanzapine, while aripiprazole was not effective in reversing the impairment induced by MK-801. Additionally, lurasidone significantly reversed memory impairment induced by the anticholinergic drug scopolamine in the passive avoidance task. The reversal of pharmacologically induced cognitive deficits in rats by lurasidone is promising \& warrants specific investigation in subjects with schizophrenia, given the prominence of cognitive deficits in this disorder.
From a different therapeutic perspective, the utility of cognitive remediation in ameliorating cognitive deficits \& improving functional outcomes in schizophrenia has recently been evaluated in several studies. A meta-analysis of these trials found effect sizes for improvement in cognitive \& psychosocial functioning in the low to moderate range (McGurck 2007). The best outcomes in psychosocial functioning were evident when cognitive remediation was combined with teaching of psychosocial skills.
Given the recalcitrant nature of cognitive deficits in schizophrenia \& their impact on functional capacity we felt that in designing a study to test the effectiveness of cognitive remediation we should maximize the likelihood of therapeutic benefit by administering cognitive remediation in the context of pharmacotherapy that may have potential for precognitive effects. By so doing we could possibly boost the effect sizes seen with cognitive remediation alone. In this study we will transition patients with schizophrenia (in whom a change in antipsychotic therapy is clinically warranted) from their current antipsychotic to lurasidone - clinicians will have eight weeks to complete the switch. Subjects who are successfully switched to lurasidone will then be randomized to receive either cognitive remediation or a non-specific mental activity control condition two times/week for a total of 30 sessions over a 4-6 month period. Our goal is to have 140 patients complete the cognitive remediation phase.
A subset of the sample will participate in 2 biomarker studies. Event related potentials \& fMRI will be done in these subjects at baseline \& study completion.
This study will be done as an Investigator initiated trial (J. Lieberman, M.D. - PI) under a separate IND.
Primary Aim: We hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score \& Cognitive Assessment Interview).
Additional aims
1. To compare cognitive remediation to active control on functional outcome as assessed by the change in UCSD Performance-Based Skills Assessment (UPSA-Brief) from baseline to end point of cognitive remediation phase.
2. To compare cognitive remediation to active control on changes from lurasidone stabilized baseline to end point in indices of functional brain activation (ERP \& fMRI) during cognitive activation tasks.
3. Evaluate the effect of 8 weeks of lurasidone treatment on cognitive \& functional outcomes as assessed by changes from baseline in the MATRICS composite score, CAI, \& UPSA-Brief.
4. Evaluate the effect of cognitive remediation compared to nonspecific mental activity on cognitive \& functional outcomes as assessed by changes from lurasidone stabilized baseline to end of cognitive remediation phase in the MATRICS composite score, CAI, \& UPSA-Brief.
5. Evaluate the efficacy, safety, \& tolerability of lurasidone in patients with schizophrenia as assessed by the change from baseline to week 8 \& to end of cognitive remediation phase in the PANSS total score, Side Effect Checklist, AIMS, SAS, BAS, \& frequency of abnormal laboratory values.
Lurasidone is a novel compound synthesized by SEPRACOR, Inc.for the treatment of patients with schizophrenia \& bipolar disorder. It possesses high affinity for dopamine D2, serotonin 5-HT2A, 5-HT7, 5-HT1A \& noradrenaline α2C receptors. Compared with other atypical antipsychotics, lurasidone demonstrates similar binding affinities for the D2 \& 5-HT2A receptors, but greater affinity for serotonin 5-HT1A receptors. Lurasidone displays no affinity for histamine H1 or acetylcholine M1 receptors. In animal studies, lurasidone significantly reversed memory impairment induced by MK-801, an N-methyl-D-aspartate (NMDA) receptor antagonist, in a rat step-through type passive avoidance task. The maximum inhibitory effects of lurasidone were greater than those observed with risperidone, quetiapine, \& olanzapine, while aripiprazole was not effective in reversing the impairment induced by MK-801. Additionally, lurasidone significantly reversed memory impairment induced by the anticholinergic drug scopolamine in the passive avoidance task. The reversal of pharmacologically induced cognitive deficits in rats by lurasidone is promising \& warrants specific investigation in subjects with schizophrenia, given the prominence of cognitive deficits in this disorder.
From a different therapeutic perspective, the utility of cognitive remediation in ameliorating cognitive deficits \& improving functional outcomes in schizophrenia has recently been evaluated in several studies. A meta-analysis of these trials found effect sizes for improvement in cognitive \& psychosocial functioning in the low to moderate range (McGurck 2007). The best outcomes in psychosocial functioning were evident when cognitive remediation was combined with teaching of psychosocial skills.
Given the recalcitrant nature of cognitive deficits in schizophrenia \& their impact on functional capacity we felt that in designing a study to test the effectiveness of cognitive remediation we should maximize the likelihood of therapeutic benefit by administering cognitive remediation in the context of pharmacotherapy that may have potential for precognitive effects. By so doing we could possibly boost the effect sizes seen with cognitive remediation alone. In this study we will transition patients with schizophrenia (in whom a change in antipsychotic therapy is clinically warranted) from their current antipsychotic to lurasidone - clinicians will have eight weeks to complete the switch. Subjects who are successfully switched to lurasidone will then be randomized to receive either cognitive remediation or a non-specific mental activity control condition two times/week for a total of 30 sessions over a 4-6 month period. Our goal is to have 140 patients complete the cognitive remediation phase.
A subset of the sample will participate in 2 biomarker studies. Event related potentials \& fMRI will be done in these subjects at baseline \& study completion.
This study will be done as an Investigator initiated trial (J. Lieberman, M.D. - PI) under a separate IND.
Primary Aim: We hypothesize that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score \& Cognitive Assessment Interview).
Additional aims
1. To compare cognitive remediation to active control on functional outcome as assessed by the change in UCSD Performance-Based Skills Assessment (UPSA-Brief) from baseline to end point of cognitive remediation phase.
2. To compare cognitive remediation to active control on changes from lurasidone stabilized baseline to end point in indices of functional brain activation (ERP \& fMRI) during cognitive activation tasks.
3. Evaluate the effect of 8 weeks of lurasidone treatment on cognitive \& functional outcomes as assessed by changes from baseline in the MATRICS composite score, CAI, \& UPSA-Brief.
4. Evaluate the effect of cognitive remediation compared to nonspecific mental activity on cognitive \& functional outcomes as assessed by changes from lurasidone stabilized baseline to end of cognitive remediation phase in the MATRICS composite score, CAI, \& UPSA-Brief.
5. Evaluate the efficacy, safety, \& tolerability of lurasidone in patients with schizophrenia as assessed by the change from baseline to week 8 \& to end of cognitive remediation phase in the PANSS total score, Side Effect Checklist, AIMS, SAS, BAS, \& frequency of abnormal laboratory values.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Schizophrenia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cognitive Remediation
Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Group Type
EXPERIMENTAL
Cognitive Remediation
Intervention Type
DRUG
Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Cognitive activity control group
This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Remediation
Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female between 18-55 years of age who meet DSM-IV-TR criteria for schizophrenia or schizoaffective disorder confirmed by the Structured Clinical Interview for DSM-IV Clinical trial version (SCID-CT version). Duration of illness \> 1 year. Outpatient status.
* Change in antipsychotic medication is clinically warranted as evidenced by
* persistent psychosis despite adequate dose and duration of antipsychotic, or \* inability to achieve therapeutic dose because of dose-limiting side effects,
* persistent side effects that either cause significant subjective distress or significantly increase medical risks, such as substantial weight gain or metabolic disturbances, or
* patient preference to switch and treating psychiatrist is in agreement.
* No behaviors suggesting potential danger to self or others over the 6 months prior to participation.
* For the last 2 weeks of lurasidone stabilization phase, a score of 4 or less on PANSS items of conceptual disorganization, hallucinations, suspiciousness and unusual thought content items.
* At end of lurasidone stabilization phase, Simpson-Angus Scale total score \<
* At end of lurasidone stabilization phase, Calgary Depression Scale total score \<10.
* No acute medical problems; any chronic medical condition (e.g. hypertension) consistently treated and stable during the 1 month prior to participation.
* Able to provide signed informed consent and to cooperate with all study procedures.
* Able to attend twice weekly sessions (each lasting approximately 75 minutes) for cognitive remediation or active control sessions for the \~6 month duration of the cognitive remediation phase of the study.
* Must meet the following cognitive performance criteria:
* Able to complete the baseline MATRICS validly at baseline as assessed by NP tester.
* Raw score of 12 or greater on the WTAR (Wechsler Test of Adult Reading) at screening.
* Women who can become pregnant must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. Acceptable methods include oral, injectable or implanted contraceptives, intrauterine devices or barrier methods such as condoms, diaphragm and spermicides. Women who can become pregnant must have a negative urine pregnancy test at the Screening Visit. Women who can become pregnant include anyone who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy), or is not postmenopausal (defined as amenorrhea 12 consecutive months).
* Change in antipsychotic medication is clinically warranted as evidenced by
* persistent psychosis despite adequate dose and duration of antipsychotic, or \* inability to achieve therapeutic dose because of dose-limiting side effects,
* persistent side effects that either cause significant subjective distress or significantly increase medical risks, such as substantial weight gain or metabolic disturbances, or
* patient preference to switch and treating psychiatrist is in agreement.
* No behaviors suggesting potential danger to self or others over the 6 months prior to participation.
* For the last 2 weeks of lurasidone stabilization phase, a score of 4 or less on PANSS items of conceptual disorganization, hallucinations, suspiciousness and unusual thought content items.
* At end of lurasidone stabilization phase, Simpson-Angus Scale total score \<
* At end of lurasidone stabilization phase, Calgary Depression Scale total score \<10.
* No acute medical problems; any chronic medical condition (e.g. hypertension) consistently treated and stable during the 1 month prior to participation.
* Able to provide signed informed consent and to cooperate with all study procedures.
* Able to attend twice weekly sessions (each lasting approximately 75 minutes) for cognitive remediation or active control sessions for the \~6 month duration of the cognitive remediation phase of the study.
* Must meet the following cognitive performance criteria:
* Able to complete the baseline MATRICS validly at baseline as assessed by NP tester.
* Raw score of 12 or greater on the WTAR (Wechsler Test of Adult Reading) at screening.
* Women who can become pregnant must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. Acceptable methods include oral, injectable or implanted contraceptives, intrauterine devices or barrier methods such as condoms, diaphragm and spermicides. Women who can become pregnant must have a negative urine pregnancy test at the Screening Visit. Women who can become pregnant include anyone who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy), or is not postmenopausal (defined as amenorrhea 12 consecutive months).
Exclusion Criteria
* Documented history of learning disability.
* Hearing or visual impairment; not fluent in English.
* Current treatment with clozapine or history of treatment resistance as evidenced by failure to improve (in the judgment of the investigator) with 2 or more adequate dose antipsychotic trials of at least 6 weeks duration in preceding 1 year.
* Concomitant or anticipated treatment with potent CYP 3A4 inhibitor such a cimetidine, cyclosporine, erythromycin or erythromycin-like drugs (e.g., azithromycin, clarithromycin except short term acute treatment for 1 week or less), diltiazem, itraconazole, ketoconazole or other systemic antifungal agents in the azole class, nefazodone; or potent CYP3A4 inducer including: carbamazepine, modafinil, Phenobarbital, phenytoin, rifampin, St. Johns Wort, and troglitazone.
* Current treatment with psychotropic agents known to affect cognition such as amphetamines, topiramate.
* History of treatment with electroconvulsive therapy within the 6 months prior to participation or expectation that patient may require ECT during the study.
* History of neurological or neuropsychiatric conditions (e.g. stroke, traumatic brain injury, epilepsy, etc).
* Subjects with a history of clinically significant neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorders (e.g. unstable angina, decompensate congestive heart failure, CNS infection or history of HIV seropositivity), which would pose a risk to the patient if they were to participate in the study or that might confound the results of the study. Active medical conditions that are minor or well controlled are not exclusionary if they do not affect risk to the patient of the study results. For example, the following are not exclusionary: a) stable and well-controlled hypertension; b) asthma (no serious attacks in the past year); c) hypothyroidism (TSH within normal limits).
* A positive test for Hepatitis C antibody with concurrent evidence of impaired hepatic function (increased AST or ALT greater than 2 times the upper limit of normal) or positive tests for Hepatitis A antibody IgM fraction or Hepatitis B surface antigen, irrespective of the AST or ALT values.
* History of alcohol or substance abuse or dependence during the 6 months prior to participation.
* Participation in a clinical trial involving an investigational medication within 3 months prior to participation or 2 or more investigational drug trials in the preceding 12 months.
* Pregnant women or women of child-bearing potential who are not using adequate birth control.
* Woman who are breast feeding.
* Individuals who: a) received any cognitive remediation in the 6 months prior to study entry or b)received more than 6 hours of cognitive remediation in the 12 months prior to study entry or c) received more than 15 hours in the 24 months prior to study entry. Cognitive remediation is defined as any behavioral intervention consisting of training activities that aim to target impairments in cognitive domains of sensory processing, attention, memory, processing speed, working memory, and executive functioning.
* Hearing or visual impairment; not fluent in English.
* Current treatment with clozapine or history of treatment resistance as evidenced by failure to improve (in the judgment of the investigator) with 2 or more adequate dose antipsychotic trials of at least 6 weeks duration in preceding 1 year.
* Concomitant or anticipated treatment with potent CYP 3A4 inhibitor such a cimetidine, cyclosporine, erythromycin or erythromycin-like drugs (e.g., azithromycin, clarithromycin except short term acute treatment for 1 week or less), diltiazem, itraconazole, ketoconazole or other systemic antifungal agents in the azole class, nefazodone; or potent CYP3A4 inducer including: carbamazepine, modafinil, Phenobarbital, phenytoin, rifampin, St. Johns Wort, and troglitazone.
* Current treatment with psychotropic agents known to affect cognition such as amphetamines, topiramate.
* History of treatment with electroconvulsive therapy within the 6 months prior to participation or expectation that patient may require ECT during the study.
* History of neurological or neuropsychiatric conditions (e.g. stroke, traumatic brain injury, epilepsy, etc).
* Subjects with a history of clinically significant neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, and/or urological disorders (e.g. unstable angina, decompensate congestive heart failure, CNS infection or history of HIV seropositivity), which would pose a risk to the patient if they were to participate in the study or that might confound the results of the study. Active medical conditions that are minor or well controlled are not exclusionary if they do not affect risk to the patient of the study results. For example, the following are not exclusionary: a) stable and well-controlled hypertension; b) asthma (no serious attacks in the past year); c) hypothyroidism (TSH within normal limits).
* A positive test for Hepatitis C antibody with concurrent evidence of impaired hepatic function (increased AST or ALT greater than 2 times the upper limit of normal) or positive tests for Hepatitis A antibody IgM fraction or Hepatitis B surface antigen, irrespective of the AST or ALT values.
* History of alcohol or substance abuse or dependence during the 6 months prior to participation.
* Participation in a clinical trial involving an investigational medication within 3 months prior to participation or 2 or more investigational drug trials in the preceding 12 months.
* Pregnant women or women of child-bearing potential who are not using adequate birth control.
* Woman who are breast feeding.
* Individuals who: a) received any cognitive remediation in the 6 months prior to study entry or b)received more than 6 hours of cognitive remediation in the 12 months prior to study entry or c) received more than 15 hours in the 24 months prior to study entry. Cognitive remediation is defined as any behavioral intervention consisting of training activities that aim to target impairments in cognitive domains of sensory processing, attention, memory, processing speed, working memory, and executive functioning.
Minimum Eligible Age
18 Years
Maximum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York State Psychiatric Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeffrey Lieberman, M.D.
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Zafar Sharif, M.D.
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Fernando Mental Health Center
Granada Hills, California, United States
Site Status
University of California - Irvine
Orange, California, United States
Site Status
Yale University
New Haven, Connecticut, United States
Site Status
University of Miami Department of Psychiatry
Miami, Florida, United States
Site Status
Medical College of Georgia
Augusta, Georgia, United States
Site Status
Northwestern University
Chicago, Illinois, United States
Site Status
Rush University Psychiatric Clinical Research Center
Chicago, Illinois, United States
Site Status
Indiana University
Indianapolis, Indiana, United States
Site Status
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site Status
University of Minnesota
Minneapolis, Minnesota, United States
Site Status
University of Missouri
Columbia, Missouri, United States
Site Status
Columbia University
New York, New York, United States
Site Status
Psychopharmacology Research Unit- Nathan KIine Institute for Psychiatric Research
New York, New York, United States
Site Status
Duke University Medical Center
Butner, North Carolina, United States
Site Status
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Site Status
University of Texas Health Science Center, San Antonio
San Antonio, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Baddeley A. Working memory. Science. 1992 Jan 31;255(5044):556-9. doi: 10.1126/science.1736359.
Reference Type
BACKGROUND
Bruder GE, Wexler BE, Sage MM, Gil RB, Gorman JM. Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits. Schizophr Res. 2004 Jun 1;68(2-3):137-47. doi: 10.1016/S0920-9964(03)00156-7.
Reference Type
BACKGROUND
Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD. Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry. 1998 Sep;155(9):1285-7. doi: 10.1176/ajp.155.9.1285.
Reference Type
BACKGROUND
Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rossler A, Kahn RS. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15.
Reference Type
BACKGROUND
Elger CE, Grunwald T, Lehnertz K, Kutas M, Helmstaedter C, Brockhaus A, Van Roost D, Heinze HJ. Human temporal lobe potentials in verbal learning and memory processes. Neuropsychologia. 1997 May;35(5):657-67. doi: 10.1016/s0028-3932(96)00110-8.
Reference Type
BACKGROUND
Fisher M, Holland C, Merzenich MM, Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am J Psychiatry. 2009 Jul;166(7):805-11. doi: 10.1176/appi.ajp.2009.08050757. Epub 2009 May 15.
Reference Type
BACKGROUND
Goldman-Rakic PS. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol Psychiatry. 1999 Sep 1;46(5):650-61. doi: 10.1016/s0006-3223(99)00130-4.
Reference Type
BACKGROUND
Goldman-Rakic PS. Working memory dysfunction in schizophrenia. J Neuropsychiatry Clin Neurosci. 1994 Fall;6(4):348-57. doi: 10.1176/jnp.6.4.348.
Reference Type
BACKGROUND
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004 Dec 15;72(1):41-51. doi: 10.1016/j.schres.2004.09.009.
Reference Type
BACKGROUND
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996 Mar;153(3):321-30. doi: 10.1176/ajp.153.3.321.
Reference Type
BACKGROUND
Gur RE, Jaggi JL, Shtasel DL, Ragland JD, Gur RC. Cerebral blood flow in schizophrenia: effects of memory processing on regional activation. Biol Psychiatry. 1994 Jan 1;35(1):3-15. doi: 10.1016/0006-3223(94)91160-6.
Reference Type
BACKGROUND
Kayser J, Bruder GE, Friedman D, Tenke CE, Amador XF, Clark SC, Malaspina D, Gorman JM. Brain event-related potentials (ERPs) in schizophrenia during a word recognition memory task. Int J Psychophysiol. 1999 Dec;34(3):249-65. doi: 10.1016/s0167-8760(99)00082-3.
Reference Type
BACKGROUND
Kayser J, Tenke CE. Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: I. Evaluation with auditory oddball tasks. Clin Neurophysiol. 2006 Feb;117(2):348-68. doi: 10.1016/j.clinph.2005.08.034. Epub 2005 Dec 13.
Reference Type
BACKGROUND
Kayser J, Tenke CE. Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: II. Adequacy of low-density estimates. Clin Neurophysiol. 2006 Feb;117(2):369-80. doi: 10.1016/j.clinph.2005.08.033. Epub 2005 Dec 13.
Reference Type
BACKGROUND
Kayser J, Tenke CE, Gates NA, Kroppmann CJ, Gil RB, Bruder GE. ERP/CSD indices of impaired verbal working memory subprocesses in schizophrenia. Psychophysiology. 2006 May;43(3):237-52. doi: 10.1111/j.1469-8986.2006.00398.x.
Reference Type
BACKGROUND
Kayser J, Tenke CE, Gates NA, Bruder GE. Reference-independent ERP old/new effects of auditory and visual word recognition memory: Joint extraction of stimulus- and response-locked neuronal generator patterns. Psychophysiology. 2007 Nov;44(6):949-67. doi: 10.1111/j.1469-8986.2007.00562.x. Epub 2007 Jul 19.
Reference Type
BACKGROUND
Sambataro F, Reed JD, Murty VP, Das S, Tan HY, Callicott JH, Weinberger DR, Mattay VS. Catechol-O-methyltransferase valine(158)methionine polymorphism modulates brain networks underlying working memory across adulthood. Biol Psychiatry. 2009 Sep 15;66(6):540-8. doi: 10.1016/j.biopsych.2009.04.014. Epub 2009 Jun 17.
Reference Type
BACKGROUND
McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry. 2007 Dec;164(12):1791-802. doi: 10.1176/appi.ajp.2007.07060906.
Reference Type
BACKGROUND
McMahon RP, Arndt S, Conley RR. More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. Stat Med. 2005 Jan 15;24(1):11-21. doi: 10.1002/sim.1837.
Reference Type
BACKGROUND
Mozley LH, Gur RC, Gur RE, Mozley PD, Alavi A. Relationships between verbal memory performance and the cerebral distribution of fluorodeoxyglucose in patients with schizophrenia. Biol Psychiatry. 1996 Sep 15;40(6):443-51. doi: 10.1016/0006-3223(95)00421-1.
Reference Type
BACKGROUND
Nichols TE, Holmes AP. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 2002 Jan;15(1):1-25. doi: 10.1002/hbm.1058.
Reference Type
BACKGROUND
Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004 Dec 15;72(1):29-39. doi: 10.1016/j.schres.2004.09.007.
Reference Type
BACKGROUND
Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry. 1992 Dec;49(12):975-82. doi: 10.1001/archpsyc.1992.01820120063009.
Reference Type
BACKGROUND
Perrin F, Pernier J, Bertrand O, Echallier JF. Spherical splines for scalp potential and current density mapping. Electroencephalogr Clin Neurophysiol. 1989 Feb;72(2):184-7. doi: 10.1016/0013-4694(89)90180-6.
Reference Type
BACKGROUND
Ragland JD, Gur RC, Raz J, Schroeder L, Kohler CG, Smith RJ, Alavi A, Gur RE. Effect of schizophrenia on frontotemporal activity during word encoding and recognition: a PET cerebral blood flow study. Am J Psychiatry. 2001 Jul;158(7):1114-25. doi: 10.1176/appi.ajp.158.7.1114.
Reference Type
BACKGROUND
Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991 Jul;48(7):618-24. doi: 10.1001/archpsyc.1991.01810310036007.
Reference Type
BACKGROUND
Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry. 2001 Dec 1;50(11):825-44. doi: 10.1016/s0006-3223(01)01252-5.
Reference Type
BACKGROUND
Wexler BE, Stevens AA, Bowers AA, Sernyak MJ, Goldman-Rakic PS. Word and tone working memory deficits in schizophrenia. Arch Gen Psychiatry. 1998 Dec;55(12):1093-6. doi: 10.1001/archpsyc.55.12.1093.
Reference Type
BACKGROUND
Wykes T, Brammer M, Mellers J, Bray P, Reeder C, Williams C, Corner J. Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia. Br J Psychiatry. 2002 Aug;181:144-52. doi: 10.1017/s0007125000161872.
Reference Type
BACKGROUND
Westfall PH. 1997. Multiple testing of general contrasts using logical constraints and correlations, J Am Stat Assoc, 92; 299-306.
Reference Type
BACKGROUND
Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y. Multiple comparisons and multiple tests using the SAS7 system, SAS Institute, Inc., Cary NC, pp. 149-175, 335-343, 1999.
Reference Type
BACKGROUND
Schafer, JL. Analysis of Incomplete Multivariate Data, New York: Chapman and Hall. 1997
Reference Type
BACKGROUND
Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 2003 May 13;100(10):6186-91. doi: 10.1073/pnas.0931309100. Epub 2003 Apr 25.
Reference Type
BACKGROUND
Little RJA, and Rubin DB. Statistical Analysis with Missing Data, Second Edition, New York: John Wiley & Sons, Inc. 2002.
Reference Type
BACKGROUND
Cohen JD, Forman SD, Braver TS, Casey BJ, Servan-Schreiber D, Noll DC. Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapp. 1994;1(4):293-304. doi: 10.1002/hbm.460010407.
Reference Type
BACKGROUND
Friedman D. ERPs during continuous recognition memory for words. Biol Psychol. 1990 Feb;30(1):61-87. doi: 10.1016/0301-0511(90)90091-a.
Reference Type
BACKGROUND
Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics, 6, 65-70, 1979.
Reference Type
BACKGROUND
Kayser, J., Tenke, C.E. Consensus on PCA for ERP data, and sensibility of unrestricted solutions. Clinical Neurophysiology, 117(3), 703-707. (2006c).
Reference Type
BACKGROUND
Kantrowitz JT, Sharif Z, Medalia A, Keefe RS, Harvey P, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA. A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. J Clin Psychiatry. 2016 Jun;77(6):799-806. doi: 10.4088/JCP.15m09998.
Reference Type
RESULT
Roberts MT, Lloyd J, Valimaki M, Ho GW, Freemantle M, Bekefi AZ. Video games for people with schizophrenia. Cochrane Database Syst Rev. 2021 Feb 4;2(2):CD012844. doi: 10.1002/14651858.CD012844.pub2.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
#6121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cognitive Remediation of Schizophrenia in a Community Mental Health Setting
NCT01988714
COMPLETED
NA
A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia
NCT00088634
COMPLETED
PHASE2
Cognitive Remediation in Early Phase Psychosis
NCT01546467
UNKNOWN
NA
Improving Accessibility and Personalization of CR for Schizophrenia
NCT03576976
COMPLETED
NA
Cognitive Remediation and Functional Skills Training in Schizophrenia
NCT01175642
COMPLETED
EARLY_PHASE1
Brain Activation Patterns in Schizophrenia After Computerized Cognitive Skills Training
NCT00431223
COMPLETED
NA
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)
NCT05351736
UNKNOWN
PHASE4
Action-based Cognitive Remediation for First Episode Psychosis
NCT03814122
COMPLETED
NA
Treatment Response to Rehabilitation in Patients With Schizophrenia
NCT00063336
COMPLETED
NA
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
NCT01569659
COMPLETED
PHASE4
Efficacy of Lu 31-130 in Patients With Schizophrenia
NCT00768326
COMPLETED
PHASE2
Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels
NCT02341131
COMPLETED
NA
Serotonin 1A Agonists and Cognition in Schizophrenia
NCT00178971
COMPLETED
PHASE3
Lurasidone Non-Interventional Study in Schizophrenia Patients
NCT06527885
COMPLETED
Cognitive Remediation in Schizophrenia
NCT01903707
UNKNOWN
NA
Cognitive Remediation for Coordinated Specialty Care
NCT03930251
SUSPENDED
NA
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia
NCT03772951
COMPLETED
PHASE4
Treatment Study for Cognitive Deficits in Schizophrenia
NCT00505076
COMPLETED
PHASE2
Evaluation of a Visual Remediation Intervention for Schizophrenia
NCT03117452
UNKNOWN
NA
Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy
NCT05140135
WITHDRAWN
NA
Treating Thought Problems in Patients With Schizophrenia
NCT00051740
COMPLETED
NA
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
NCT02534363
COMPLETED
PHASE4
Clinical Study Of Schizophrenia in Both Men and Women
NCT00071747
COMPLETED
PHASE3
Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
NCT02714894
UNKNOWN
Specific Cognitive Remediation for Schizophrenia
NCT01607424
COMPLETED
NA